NLS Pharmaceutics and Kadimastem have announced the initial closing of a $500,000 fundraising effort, part of a larger $1 million initiative aimed at facilitating a proposed merger between the two ...
Christine Allen, CEO and Co-Founder of Intrepid Labs, and Andy Lewis, CSO at Quotient Sciences, highlight their strategic ...
Welltica+ on MSN
New hope for diabetics – insulin could become a pill
Researchers have been working for many years on a solution that could make treatment easier for people with diabetes. Now, ...
ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of ...
(RTTNews) - NLS Pharmaceutics AG (NLSP) and Kadimastem Ltd. (KDST.TA), which announced their plan to form a combined Nasdaq-listed biotechnology company last month, have today introduced a new ...
We are delighted to share a summary of NLS Pharmaceutics' achieved milestones since the fourth quarter of 2024. Here's a snapshot of our progress and what lies ahead: Since we first announced the ...
Last year, the Royal Pharmaceutical Society of Great Britain held a consultation regarding how the profession should develop during the next 12 years. An analysis of the results has just been ...
Mark Egerton, PhD, chief executive officer of Quotient Sciences, shares insights on a new approach to accelerate drug development, which integrates formulation development, real-time adaptive GMP ...
NLS Pharmaceutics (NASDAQ:NLSP) rose in premarket trading on Monday after the company reported a definitive merger agreement with Kadimastem. NLSP (NLSP) stock climbed +57.22% to $5.66 +2.06 premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results